SI-BONE’s (SIBN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

SI-BONE (NASDAQ:SIBN)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They currently have a $25.00 price objective on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 37.74% from the stock’s previous close.

Several other research analysts also recently commented on SIBN. Truist Financial boosted their price objective on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Needham & Company LLC boosted their price target on SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $24.50.

SI-BONE Stock Performance

SIBN opened at $18.15 on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE has a 52-week low of $11.70 and a 52-week high of $19.19. The firm has a market cap of $761.17 million, a P/E ratio of -19.73 and a beta of 1.17. The business’s fifty day moving average is $15.91 and its 200-day moving average is $14.74.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $49.00 million for the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Sell-side analysts expect that SI-BONE will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling at SI-BONE

In other news, CFO Anshul Maheshwari sold 5,304 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the transaction, the chief financial officer now owns 189,319 shares of the company’s stock, valued at $2,633,427.29. This represents a 2.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the sale, the insider now owns 222,814 shares in the company, valued at approximately $3,097,114.60. This represents a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,311 shares of company stock worth $130,356 over the last quarter. Corporate insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On SI-BONE

Large investors have recently modified their holdings of the business. Paradigm Capital Management Inc. NY grew its stake in shares of SI-BONE by 5.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company’s stock worth $19,432,000 after purchasing an additional 69,831 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of SI-BONE by 8.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,666 shares of the company’s stock valued at $1,439,000 after buying an additional 7,855 shares during the last quarter. Virtus Fund Advisers LLC acquired a new stake in shares of SI-BONE in the fourth quarter valued at about $40,000. Virtus Investment Advisers Inc. acquired a new stake in shares of SI-BONE in the fourth quarter valued at about $196,000. Finally, Squarepoint Ops LLC bought a new position in shares of SI-BONE during the fourth quarter worth about $449,000. Institutional investors own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.